Allenex AB (LTS:0O9J) Debt-to-Equity : 0.51 (As of Mar. 2016)

View and export this data going back to . Start your Free Trial

What is Allenex AB Debt-to-Equity?

Allenex AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was £0.86 Mil. Allenex AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was £8.21 Mil. Allenex AB's Total Stockholders Equity for the quarter that ended in Mar. 2016 was £17.70 Mil. Allenex AB's debt to equity for the quarter that ended in Mar. 2016 was 0.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Allenex AB's Debt-to-Equity or its related term are showing as below:

LTS:0O9J' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 0.51

LTS:0O9J's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs LTS:0O9J: 0.51

Allenex AB Debt-to-Equity Historical Data

The historical data trend for Allenex AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allenex AB Debt-to-Equity Chart

Allenex AB Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-Equity

Get a 7-Day Free Trial

0.68

0.45

0.43

0.40

0.52

Allenex AB Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Debt-to-Equity	Get a 7-Day Free Trial															0.55	0.55	0.54	0.52	0.51

Competitive Comparison of Allenex AB's Debt-to-Equity

For the Biotechnology subindustry, Allenex AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allenex AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allenex AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Allenex AB's Debt-to-Equity falls into.

Allenex AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Allenex AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.66	+	6.911)	/	16.476
	=	0.52

Allenex AB's Debt to Equity Ratio for the quarter that ended in Mar. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.856	+	8.207)	/	17.696
	=	0.51

Allenex AB (LTS:0O9J) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Allenex AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Allenex AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Allenex AB (LTS:0O9J) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allenex AB (LTS:0O9J) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.allenex.com

Allenex AB creates life-science companies in collaboration with innovators. The process requires identifying ideas with commercial potential, and then contributing entrepreneurship and capital. Its portfolio consists of twelve companies, four in drug development and biotechnology, and eight in diagnostics and medical technologies. The company portfolio accounts for more than 50 different projects, some nearing the commercialization phase while others are already selling their products of services, in a wide range of therapeutic areas- from HIV and cancer to eye disease and allergies. Its Drug Development and Biotechnology business area is comprised of four companies: Anamar Medical, IMED, Novahep, and Recopharma. Anamar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and osteoarthritis, with five drug candidates' two biomarkets, and two commercial biomarkers. IMED develops human monoclonal antibodies (MAB) that induce or block natural cell death or apoptosis, and intending to develop antibodies for major therapeutic areas, including HIV, cancer, and transplantation. Novahep, in collaboration with the Karolinska Institute, aims to differentiate cell lines of fetal liver stem cells, which can then be used in the transplantation sector. Recopharma develops mucins for the vaccine market and antimicrobial substances to combat bacteria and viruses that may cause eye infection, influenza, and the Norwalk virus. The companies in the Diagnostics and Medical Technology business area include Absorber, Bioresonator, Biovator, Likvor, Olerup, Olerup SSP, Oncolog, Ortoviva, and Pharmacolog. These companies develop products such as the XM-ONE transplantation test, biomedical sensors, allergic reaction testing technology for the pharmaceutical, cosmetic and chemical industries, a diagnostic instrument to measure cerebrospinal fluid pressure (CSF), tools to facilitate the insertion of artificial discs in spinal surgery, and systems to control the content and concentration of liquid pharmaceutical drugs.

Allenex AB (LTS:0O9J) Headlines

No Headlines